This Blog AMICOR is a communication instrument of a group of friends primarily interested in health promotion, with a focus on cardiovascular diseases prevention.
To contact send a message to
achutti@gmail.com
http://achutti.blogspot.com
In older patients with diabetes, use of metformin was linked with slower cognitive decline and reduced risk of dementia, according to a prospective observational /.../study.
Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis (Vujkovic et al.) https://go.nature.com/3e2QmYc
For the first time, antihyperglycemic therapies are available to modify cardiovascular disease courses in type 2 diabetes . Two therapeutic classes (sodium-glucose cotransporter inhibitors and glucagon-like peptide-1 receptor agonists) are now recognized to be associated with multisystem health and reductions in cardiovascular and kidney outcomes. Despite the ongoing expansion of the evidentiary base supporting their use and the broadening of regulatory labels of select sodium-glucose cotransporter inhibitors and glucagon-like peptide-1 receptor agonists, their prescription has been largely restricted to primary care physicians and endocrinologists.1,2 Primary care physicians treat approximately 90% of individuals with type 2 diabetes nationally.3 However, high-risk patients with type 2 diabetes commonly encounter various internal medicine specialists because of high rates of comorbidities and clinical events.4 We therefore characterized the distribution of internal medicine specialists in the United States who may be able to provide care for the growing population with diabetes.
The FDA approved dapagliflozin (Farxiga) to reduce heart failure (HF) hospitalization risk in adults with type 2 diabetes at elevated risk due to established cardiovascular disease or multiple risk factors for it, AstraZeneca announced.
Dapagliflozin is the first selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) to gain that particular supplemental indication.
Just last month, SGLT2 inhibitor canagliflozin (Invokana)got an indication to reduce HF admissions and other cardiovascular events among type 2 diabetes patients with diabetic kidney disease.
Dapagliflozin's new indication was based on the DECLARE-TIMI 58 trial. Although the trial missed the primary endpoint for major adverse cardiovascular events, it met the other by reducing risk of cardiovascular death or hospitalization for heart failure by 17% versus placebo -- driven entirely by HF admission reduction./.../
What to know about glycosuria Glycosuria is where the urine contains more blood sugar (glucose) than usual. Diabetes and kidney disease can cause glycosuria. Learn about the causes, symptoms, and treatments here.
